|
Oncogenes and Tumor Suppressors
Citations 441-450 of 795 total displayed.
|
Past content
(since May 2000):
|
Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors
- Thomas Rasmussen, Michael Kuehl, Marianne Lodahl, Hans E. Johnsen, and Inger Marie S. Dahl
Blood 2005; 105: 317-323.
[Abstract]
[Full text]
[PDF]
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis
- Steffen Koschmieder, Berthold Göttgens, Pu Zhang, Junko Iwasaki-Arai, Koichi Akashi, Jeffery L. Kutok, Tajhal Dayaram, Kristin Geary, Anthony R. Green, Daniel G. Tenen, and Claudia S. Huettner
Blood 2005; 105: 324-334.
[Abstract]
[Full text]
[PDF]
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)
- Thomas Kindler, Frank Breitenbuecher, Stefan Kasper, Eli Estey, Francis Giles, Eric Feldman, Gerhard Ehninger, Gary Schiller, Virginia Klimek, Stephen D. Nimer, Alois Gratwohl, Chuna Ram Choudhary, Constan Mueller-Tidow, Hubert Serve, Harald Gschaidmeier, Pamela S. Cohen, Christoph Huber, and Thomas Fischer
Blood 2005; 105: 335-340.
[Abstract]
[Full text]
[PDF]
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
- Hong Chang, Connie Qi, Qi-Long Yi, Donna Reece, and A. Keith Stewart
Blood 2005; 105: 358-360.
[Abstract]
[Full text]
[PDF]
Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2-/-  c-/- mice: functional inactivation of p53 in developing T cells
- Ramon Gimeno, Kees Weijer, Arie Voordouw, Christel H. Uittenbogaart, Nicolas Legrand, Nuno L. Alves, Erwin Wijnands, Bianca Blom, and Hergen Spits
Blood 2004; 104: 3886-3893.
[Abstract]
[Full text]
[PDF]
Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy
- Vahid Asnafi, Kheira Beldjord, Marta Libura, Patrick Villarese, Corrine Millien, Paola Ballerini, Emilienne Kuhlein, Marina Lafage-Pochitaloff, Eric Delabesse, Olivier Bernard, and Elizabeth Macintyre
Blood 2004; 104: 4173-4180.
[Abstract]
[Full text]
[PDF]
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells
- Kevin W. H. Yee, Marcus Schittenhelm, Anne-Marie O'Farrell, Ajia R. Town, Laura McGreevey, Troy Bainbridge, Julie M. Cherrington, and Michael C. Heinrich
Blood 2004; 104: 4202-4209.
[Abstract]
[Full text]
[PDF]
Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein
- Tong Yin, Ying-Li Wu, Hui-Ping Sun, Guan-Lin Sun, Yan-Zhi Du, Kan-Kan Wang, Ji Zhang, Guo-Qiang Chen, Sai-Juan Chen, and Zhu Chen
Blood 2004; 104: 4219-4225.
[Abstract]
[Full text]
[PDF]
Expression of SMRT promotes ligand-induced activation of mutated and wild-type retinoid receptors
- Sylvie Côté, Suzan McNamara, Daria Brambilla, Andrea Bianchini, Giovanni Rizzo, Sonia Victoria del Rincón, Francesco Grignani, Clara Nervi, and Wilson H. Miller, Jr
Blood 2004; 104: 4226-4235.
[Abstract]
[Full text]
[PDF]
Adoptive immunotherapy of BCR-ABL–induced chronic myeloid leukemia–like myeloproliferative disease in a murine model
- Daniela S. Krause and Richard A. Van Etten
Blood 2004; 104: 4236-4244.
[Abstract]
[Full text]
[PDF]
|
|
